✦ LIBER ✦

PCN1: BASELINE ANEMIA AND RISK OF POOR RESPONSE TO CHEMOTHERAPY IN INTERMEDIATE GRADE NON-HODGKIN'S LYMPHOMA(IGNHL) PATIENTS

✍ Scribed by G Lawless; S Gupta; RE Tannous

Book ID: 118613809
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 53 KB
Volume: 4
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)71561-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Impact of Age on Delivered Dose Inte

The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin's Lymphoma Receiving Initial CHOP Chemotherapy: A Risk Factor Analysis

✍ Morrison, Vicki A.; Picozzi, Vincent; Scott, Shane; Pohlman, Brad; Dickman, Elli 📂 Article 📅 2001 🏛 CIG Media Group, LP. 🌐 English ⚖ 160 KB

Risk and timing of hospitalization for f

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma

✍ Gary H. Lyman; David J. Delgado 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

## Background: Hospitalization for chemotherapy-induced febrile neutropenia is associated with substantial cost and may negatively impact clinical outcome due to associated dose attenuation. ## Methods: Medical records of 1355 patients with intermediate-grade non-hodgkin lymphoma receiving cyclop

Feasibility of peripheral blood progenit

Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: Non-Hodgkin's lymphoma

✍ F. Zallio; A. Cuttica; D. Caracciolo; P. Gavarotti; L. Bergui; F. Giaretta; P. B 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 55 KB

Role of high-dose therapy and initial re

Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin’s lymphoma: a retrospective series on 126 patients from a single center

✍ Bouabdallah, R; Coso, D; Costello, R; Bardou, V J; Blaise, D; Xerri, L; Sainty, 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 65 KB

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s